Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.


Dec 17, 2018
The AHA voiced support for a Centers for Medicare & Medicaid Services’ proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to
Dec 14, 2018
The Federal Trade Commission’s approach to reviewing hospital mergers “is overbroad, does not properly cred
Dec 11, 2018
AHA letter to Speaker Ryan and Minority Leader Pelosi expressing strong support for House passage of H.R.1318, the Preventing Maternal Deaths Act.
Dec 7, 2018
AHA comments on the National Committee on Vital and Health Statistics’ draft recommendations for the predictability roadmap.
Dec 7, 2018
AHA comments on the Department of Homeland Security’s proposed rule that could limit legal immigrants’ future immigration status based on their receipt of public benefits.
Dec 7, 2018
AHA comments on the Centers for Medicare & Medicaid Services’ (CMS) methodology for the Department of Health and Human Services-operated permanent risk adjustment program for the 2018 benefit year.
Dec 5, 2018
AHA encourages Congressional leaders to pass the Pandemic and All-Hazards Preparedness & Advancing Innovation Act (PAHPAI, S. 2852 & H.R. 6378) before Congress adjourns for 2018.
Nov 30, 2018
AHA today urged the United States Pharmacopeial Convention to delay by at least 18 months the effective dates for its general chapter pharmaceutical compounding and general chapter hazardous drug handling in health care settings, as well as proposed revisions to general chapter .
Nov 19, 2018
The AHA urges the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
Nov 19, 2018
Download the letter (PDF) below Re: CMS—3346—P, Medicare and Medicaid Programs; Regulatory Provisions To P